

Special Issue

Advances in Hereditary Colorectal Cancer: Diagnosis and Treatment

Message from the Guest Editor

Hereditary colorectal cancer syndromes account for 5–10% of all colorectal cancers and the most common forms are Lynch syndrome and familial adenomatous polyposis (FAP). Identifying persons at risk for hereditary colorectal cancer remains challenging, yet is critical for guiding prevention strategies, and for informing appropriate diagnostic tests and treatment.

Furthermore, it is important that at-risk persons of all backgrounds have access to proper diagnostic and treatment options. This Special Issue will focus on novel and effective approaches to optimize the diagnosis and treatment of hereditary colorectal cancer. Although treatment strategies differ based on the molecular and genetic profile of tumors, only a subset of tumors (colon and other Lynch-related tumors) undergo these diagnostic tests. Manuscripts will be solicited from top experts in the field covering (1) approaches to optimizing the diagnosis of hereditary colorectal cancer, (2) targeted therapies for treating hereditary colorectal cancer, and (3) strategies to assure equity for the diagnosis and treatment of hereditary colorectal cancer.

Guest Editor

Dr. Jan T. Lowery

University of Colorado Cancer Center, Aurora, CO 80045, USA

Deadline for manuscript submissions

closed (12 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/169203

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)